Home > Insider Trading > Filing (0000899243-21-022066)

Filing Details

Accession Number:: 0000899243-21-022066
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-04 17:00:38
Reporting Period:: 2021-06-02

Accepted Time:: 2021-06-04 17:00:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1847903	Centessa Pharmaceuticals Plc	CNTA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1861844	Arjun Goyal	C/O Centessa Pharmaceuticals Plc 3Rd Floor, 1 Ashley Rd, Altrincham Cheshire X0 WA14 2DT		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2021-06-02	3,095,909	$0.00	3,095,909	No	4	C	Indirect	See footnote
Ordinary Shares	Acquisiton	2021-06-02	85,909	$0.00	85,909	No	4	C	Indirect	See footnote
Ordinary Shares	Acquisiton	2021-06-02	729,750	$20.00	3,825,659	No	4	P	Indirect	See footnote
Ordinary Shares	Acquisiton	2021-06-02	20,250	$20.00	106,159	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Series A Preferred Shares	Acquisiton	2021-01-29	3,095,909	$11.00	3,095,909	$0.00
Ordinary Shares	Series A Preferred Shares	Acquisiton	2021-01-29	85,909	$11.00	85,909	$0.00
Ordinary Shares	Series A Preferred Shares	Disposition	2021-06-02	3,095,909	$0.00	3,095,909	$0.00
Ordinary Shares	Series A Preferred Shares	Disposition	2021-06-02	85,909	$0.00	85,909	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,095,909	No	4	A	Indirect
85,909	No	4	A	Indirect
0	No	4	C	Indirect
0	No	4	C	Indirect

Footnotes

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date.
Held by Vida Ventures II, LLC ("Vida II Main Fund"). VV Manager II, LLC ("VV Manager II") is the manager of Vida II Main Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Held by Vida Ventures II-A, LLC ("Vida II Parallel Fund"). VV Manager II is the manager of Vida II Parallel Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Share Split"). This amount has been adjusted to give effect to the Share Split.